Lyvgen Biopharma Funding: $30M Raised, Series B (2018)
Lyvgen Biopharma is based in Shanghai, China. It has raised $30M in total funding. Latest round: Series B.
Lyvgen Biopharma funding overview
Lyvgen Biopharma is based in Shanghai, China. Lyvgen Biopharma has raised $30M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in July 2018. The round record for Lyvgen Biopharma runs through 2018; nothing later has been disclosed. Investors on record include 6 Dimensions Capital, Winfair Global, Runling Capital, Morningside Ventures. 4 distinct backers are named across the disclosed rounds.
Lyvgen Biopharma has raised $30M in total disclosed funding across the rounds on record.
Who has invested in Lyvgen Biopharma?
6 Dimensions Capital, Winfair Global, Runling Capital, Morningside Ventures are named among the investors backing Lyvgen Biopharma.
What was the latest Lyvgen Biopharma funding round?
The most recent disclosed round is a Series B, announced in July 2018.
Where is Lyvgen Biopharma based?
Lyvgen Biopharma is based in Shanghai, China.
When did Lyvgen Biopharma last raise?
The last disclosed Lyvgen Biopharma round closed in July 2018 at Series B.
Lyvgen Biopharma totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Shanghai below to benchmark round size and investor mix.
